002252 上海莱士
已收盘 08-05 15:00:00
资讯
新帖
简况
上海莱士：公司7月推出的回购方案将全部用于注销并减少注册资本
证券之星 · 07-30
上海莱士：公司7月推出的回购方案将全部用于注销并减少注册资本
上海莱士(002252)7月20日股东户数12.11万户，较上期增加2.01%
证券之星 · 07-30
上海莱士(002252)7月20日股东户数12.11万户，较上期增加2.01%
上海莱士：截至2026年7月20日，公司股东总户数为121,087户
证券之星 · 07-30
上海莱士：截至2026年7月20日，公司股东总户数为121,087户
公司问答丨上海莱士：公司拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益
格隆汇 · 07-24
公司问答丨上海莱士：公司拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益
上海莱士：SR604抗体来自同一原始细胞株
证券之星 · 07-24
上海莱士：SR604抗体来自同一原始细胞株
上海莱士（002252）披露SR604注射液II期临床试验登记进展，7月22日股价上涨0.78%
证券之星 · 07-22
上海莱士（002252）披露SR604注射液II期临床试验登记进展，7月22日股价上涨0.78%
上海莱士：IIb期已完成24周关键用药观察期
证券之星 · 07-20
上海莱士：IIb期已完成24周关键用药观察期
上海莱士(002252)7月10日股东户数11.87万户，较上期增加1.79%
证券之星 · 07-20
上海莱士(002252)7月10日股东户数11.87万户，较上期增加1.79%
上海莱士：该案件一审判决公司无需承担任何责任
证券之星 · 07-20
上海莱士：该案件一审判决公司无需承担任何责任
7月16日上海莱士涨5.27%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 07-16
7月16日上海莱士涨5.27%，招商国证生物医药指数(LOF)C基金重仓该股
上海莱士：Equilibra正在欧美地区开展SR604在血友病预防治疗的临床试验
证券之星 · 07-16
上海莱士：Equilibra正在欧美地区开展SR604在血友病预防治疗的临床试验
上海莱士：7月10日独立董事陈岩增持股份合计2800股
证券之星 · 07-13
上海莱士：7月10日独立董事陈岩增持股份合计2800股
股市必读：上海莱士（002252）7月10日董秘有最新回复
证券之星 · 07-13
股市必读：上海莱士（002252）7月10日董秘有最新回复
上海莱士：不存在每日可查看股东户数的情况
证券之星 · 07-10
上海莱士：不存在每日可查看股东户数的情况
上海莱士：公司相关运营指标有一定改善
证券之星 · 07-10
上海莱士：公司相关运营指标有一定改善
上海莱士：基立福人血白蛋白非低端廉价产品
证券之星 · 07-10
上海莱士：基立福人血白蛋白非低端廉价产品
上海莱士（002252）披露回购公司股份方案公告，7月7日股价下跌3.46%
证券之星 · 07-07
上海莱士（002252）披露回购公司股份方案公告，7月7日股价下跌3.46%
上海莱士最新公告：拟2.5亿元至5亿元回购股份将全部用于注销并减少注册资本
证券之星 · 07-07
上海莱士最新公告：拟2.5亿元至5亿元回购股份将全部用于注销并减少注册资本
上海莱士（002252）披露完成经营范围变更登记并换发营业执照公告，7月6日股价上涨0.43%
证券之星 · 07-06
上海莱士（002252）披露完成经营范围变更登记并换发营业执照公告，7月6日股价上涨0.43%
股市必读：上海莱士（002252）7月3日董秘有最新回复
证券之星 · 07-06
股市必读：上海莱士（002252）7月3日董秘有最新回复
加载更多
公司概况
公司名称：
上海莱士血液制品股份有限公司
所属行业：
医药制造业
上市日期：
2008-06-23
主营业务：
上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。
发行价格：
12.81
{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":5.06,"timestamp":1785913395000,"preClose":5.22,"halted":0,"volume":68408221,"delay":0,"changeRate":-0.0307,"floatShares":6588000000,"shares":6593000000,"eps":0.2013,"marketStatus":"已收盘","change":-0.16,"latestTime":"08-05 15:00:00","open":5.21,"high":5.22,"low":5.04,"amount":348000000,"amplitude":0.0345,"askPrice":5.07,"askSize":1547,"bidPrice":5.06,"bidSize":1324,"shortable":0,"etf":0,"ttmEps":0.2013,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785979800000},"marketStatusCode":5,"adr":0,"adjPreClose":5.22,"symbolType":"stock","openAndCloseTimeList":[[1785893400000,1785900600000],[1785906000000,1785913200000]],"highLimit":5.74,"lowLimit":4.7,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6592672885,"isCdr":false,"pbRate":1.06,"roa":"--","peRate":25.136612,"roe":"0.97%","epsLYR":0.24,"committee":0.607785,"marketValue":33359000000,"turnoverRate":0.0104,"status":1,"floatMarketCap":33337000000},"requestUrl":"/m/hq/s/002252","defaultTab":"news","newsList":[{"id":"2655870944","title":"上海莱士：公司7月推出的回购方案将全部用于注销并减少注册资本","url":"https://stock-news.laohu8.com/highlight/detail?id=2655870944","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655870944?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:52","pubTimestamp":1785415926,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士07月29日在投资者关系平台上答复投资者关心的问题。谢谢上海莱士回复：关于股份回购：公司7月推出的回购方案将全部用于注销并减少注册资本，直接增厚每股净资产与每股收益。截至2025年末公司资金储备约28.4亿元，本次回购上限5亿元，不会挤占研发与运营资源。但公司并非原地踏步：创新药方面，全球首创品种SR604注射液I/II期关键数据表现良好，III期准备已同步启动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000037396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002252","BK0196","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820492","title":"上海莱士(002252)7月20日股东户数12.11万户，较上期增加2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820492","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655820492?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:54","pubTimestamp":1785405284,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海莱士披露，截至2026年7月20日公司股东户数为12.11万户，较7月10日增加2386.0户，增幅为2.01%。在生物制品行业个股中，上海莱士股东户数高于行业平均水平，截至7月20日，生物制品行业平均股东户数为3.58万户。从股价来看，2026年7月10日至2026年7月20日，上海莱士区间涨幅为13.97%，在此期间股东户数增加2386.0户，增幅为2.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000028302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","002252","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655448398","title":"上海莱士：截至2026年7月20日，公司股东总户数为121,087户","url":"https://stock-news.laohu8.com/highlight/detail?id=2655448398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655448398?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:36","pubTimestamp":1785382593,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止7月20号，公司的股东人数是多少？谢谢上海莱士回复：感谢您的关注！ 截至2026年7月20日，公司股东总户数为121,087户。 谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000014894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0196","BK0046","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653770428","title":"公司问答丨上海莱士：公司拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770428","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653770428?lang=zh_cn&edition=full","pubTime":"2026-07-24 15:35","pubTimestamp":1784878515,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","BK0196","002252","BK0239","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653703956","title":"上海莱士：SR604抗体来自同一原始细胞株","url":"https://stock-news.laohu8.com/highlight/detail?id=2653703956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653703956?lang=zh_cn&edition=full","pubTime":"2026-07-24 11:37","pubTimestamp":1784864247,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：美国开始临床试验的SR604是不是和莱士的是同一款产品？如果不是，美国临床的SR604是否有使用莱士的专利授权？上海莱士回复：感谢您的关注！公司的SR604抗体是在海外转让的针对活化蛋白C的小鼠杂交瘤细胞株产生的鼠抗人活化蛋白C抗体的基础上进一步研究开发的产品，美国临床的SR604和公司项目同源，来自同一原始细胞株。公司拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400016003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0188","BK0196","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653476543","title":"上海莱士（002252）披露SR604注射液II期临床试验登记进展，7月22日股价上涨0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653476543","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653476543?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:07","pubTimestamp":1784729238,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，上海莱士报收于5.18元，较前一交易日上涨0.78%，最新总市值为341.5亿元。该股当日开盘5.12元，最高5.2元，最低5.09元，成交额达4.35亿元，换手率为1.28%。上海莱士血液制品股份有限公司近日在国家药品监督管理局药物临床试验登记与信息公示平台登记了SR604注射液用于先天性凝血因子Ⅶ缺乏症的II期临床试验。SR604注射液为一种单克隆抗体制剂，此前已获准开展针对血友病A/B及先天性凝血因子Ⅶ缺乏症的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","002252","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652151032","title":"上海莱士：IIb期已完成24周关键用药观察期","url":"https://stock-news.laohu8.com/highlight/detail?id=2652151032","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652151032?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:51","pubTimestamp":1784551867,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士07月19日在投资者关系平台上答复投资者关心的问题。谢谢上海莱士回复：感谢您的关注！公司2025年可持续发展报告中2025年度研发人员数量为263人，与2025年度报告中披露的研发人员人数一致。目前正在推进Ⅲ期筹备工作。公司将根据临床关键节点进展，依规及时对外履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000037262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0028","002252","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652291249","title":"上海莱士(002252)7月10日股东户数11.87万户，较上期增加1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652291249","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652291249?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:41","pubTimestamp":1784540496,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海莱士披露，截至2026年7月10日公司股东户数为11.87万户，较6月30日增加2088.0户，增幅为1.79%。在生物制品行业个股中，上海莱士股东户数高于行业平均水平，截至7月10日，生物制品行业平均股东户数为3.57万户。从股价来看，2026年6月30日至2026年7月10日，上海莱士区间涨幅为5.53%，在此期间股东户数增加2088.0户，增幅为1.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000027269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0028","002252","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652261190","title":"上海莱士：该案件一审判决公司无需承担任何责任","url":"https://stock-news.laohu8.com/highlight/detail?id=2652261190","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652261190?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:36","pubTimestamp":1784518569,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)07月19日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好!看到公开信息，贵公司收到和发起的诉讼仲裁，合计金额2.765亿元。为啥产生的?进展如何？有无可能造成经济损失和股价波动?谢谢！上海莱士回复：感谢您的关注！您提到的诉讼事项公司已在相关年度报告以及半年度报告中披露。该案件一审判决公司无需承担任何责任，目前正在二审阶段，尚未判决。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000012594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","002252","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651055412","title":"7月16日上海莱士涨5.27%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651055412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651055412?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:27","pubTimestamp":1784190423,"startTime":"0","endTime":"0","summary":"证券之星消息，7月16日上海莱士涨5.27%，收盘报5.19元，换手率2.38%，成交量156.7万手，成交额8.03亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.1亿元，最新净值0.4108，较上一交易日上涨4.37%，近一年上涨2.75%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600026242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002252","BK0028","399441","161726","BK0188","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651418504","title":"上海莱士：Equilibra正在欧美地区开展SR604在血友病预防治疗的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2651418504","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651418504?lang=zh_cn&edition=full","pubTime":"2026-07-16 11:36","pubTimestamp":1784172969,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)07月15日在投资者关系平台上答复投资者关心的问题。投资者提问：作为公司投资者应该怎么理解Equilibra Bioscience在美国同步启动了SR604的I期临床试验？上海莱士回复：感谢您的关注！上海莱士拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益，Equilibra拥有SR604上述大中华地区以外地区的研发和商业化权益。目前Equilibra正在欧美地区开展SR604在血友病预防治疗的临床试验。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600015278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002252","BK0196","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651911412","title":"上海莱士：7月10日独立董事陈岩增持股份合计2800股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651911412","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651911412?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:01","pubTimestamp":1783947680,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月13日市场公开信息、上市公司公告及交易所披露数据整理，上海莱士最新董监高及相关人员股份变动情况：2026年7月10日公司独立董事陈岩共增持公司股份2800.0股，占公司总股本为0.0001%。上海莱士近半年内的董监高及核心技术人员增减持详情如下：上海莱士的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1665.47万，融资余额增加；融券净流出3.98万，融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300038113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0046","BK0188","BK0028","BK0239","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651716547","title":"股市必读：上海莱士（002252）7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651716547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651716547?lang=zh_cn&edition=full","pubTime":"2026-07-13 01:14","pubTimestamp":1783876450,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，上海莱士报收于4.58元，上涨2.23%，换手率1.1%，成交量72.49万手，成交额3.3亿元。中国证券登记结算有限责任公司每月向上市公司提供截至上月最后一个交易日、本月10日和本月20日的定期名册，不存在每日可查看股东户数的情况。截至2026年6月30日，公司股东总户数为116,613户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300000638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","002252","BK0028","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650884481","title":"上海莱士：不存在每日可查看股东户数的情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2650884481","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650884481?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:51","pubTimestamp":1783669874,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问：怎样才能第一时间或是每天都能看到最新的股东户数上海莱士回复：感谢您的关注！中国证券登记结算有限责任公司每月向上市公司提供截至上月最后一个交易日、本月10日和本月20日（该日为非交易日的，应为该日前一个交易日）的定期名册，不存在每日可查看股东户数的情况。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000025655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","002252","BK0239","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650118849","title":"上海莱士：公司相关运营指标有一定改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2650118849","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650118849?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:51","pubTimestamp":1783669874,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士07月10日在投资者关系平台上答复投资者关心的问题。公司全面落地营销体系重构、渠道管理、精益降本等系列改革举措，公司相关运营指标有一定改善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000025658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002252","BK0028","BK0196","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650188418","title":"上海莱士：基立福人血白蛋白非低端廉价产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2650188418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650188418?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:51","pubTimestamp":1783669871,"startTime":"0","endTime":"0","summary":"投资者提问：进入7月份，各大网购平台“最廉价人血白蛋白”继续被基立福品牌霸屏，请问“基立福人血白蛋白”的品牌定位是最低端廉价药品吗？基立福的全网最低价销售模式对基立福品牌全球其他产品形象有何影响？基立福人血白蛋白作为国际成熟的血制品品牌，公司不存在将其划定为低端、廉价产品的情况。公司自产白蛋白与基立福进口白蛋白依托各自品质、供货特点对应不同临床使用场景，二者形成良性互补格局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000025647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","BK0196","BK0188","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649171935","title":"上海莱士（002252）披露回购公司股份方案公告，7月7日股价下跌3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649171935","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649171935?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:29","pubTimestamp":1783434556,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，上海莱士报收于4.47元，较前一交易日下跌3.46%，最新总市值为294.69亿元。该股当日开盘4.61元，最高4.63元，最低4.45元，成交额达2.3亿元，换手率为0.77%。近日，上海莱士发布《关于回购公司股份方案的公告》。本次回购股份将用于注销并减少注册资本。回购实施期限为股东会审议通过之日起12个月内。本次回购不会损害公司债务履行能力和持续经营能力，公司全体董事已作出相关承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700041726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","BK0239","BK0188","002252","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982785","title":"上海莱士最新公告：拟2.5亿元至5亿元回购股份将全部用于注销并减少注册资本","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649982785?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:01","pubTimestamp":1783425675,"startTime":"0","endTime":"0","summary":"上海莱士(002252.SZ)公告称，公司董事会审议通过回购股份方案，拟使用自有资金和银行专项贷款资金，以集中竞价交易方式回购公司股份，回购资金总额不低于2.5亿元、不超过5亿元，回购股份将全部用于注销并减少注册资本。该议案尚需提交股东会审议。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700037034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002252","BK0028","BK0188","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649627600","title":"上海莱士（002252）披露完成经营范围变更登记并换发营业执照公告，7月6日股价上涨0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649627600","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649627600?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:17","pubTimestamp":1783347430,"startTime":"0","endTime":"0","summary":"截至2026年7月6日收盘，上海莱士报收于4.63元，较前一交易日上涨0.43%，最新总市值为305.24亿元。该股当日开盘4.61元，最高4.68元，最低4.56元，成交额达3.48亿元，换手率为1.14%。近日，上海莱士血液制品股份有限公司发布《关于完成经营范围变更登记并换发营业执照的公告》。公告显示，公司于2026年3月25日召开第六届董事会第十七次会议，审议通过变更公司经营范围暨修订《公司章程》的议案，并经2026年4月29日公司2025年度股东会审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600037423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","BK0196","BK0188","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649561643","title":"股市必读：上海莱士（002252）7月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649561643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649561643?lang=zh_cn&edition=full","pubTime":"2026-07-06 02:33","pubTimestamp":1783276390,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，上海莱士报收于4.61元，上涨1.77%，换手率0.94%，成交量61.83万手，成交额2.84亿元。欧美等海外国家血液制品终端价格受其医疗体系与医保支付规则、产品供需格局、临床使用场景等影响。前期国内市场体量庞大，公司经营重心主要深耕国内市场。当日关注点交易信息汇总：7月3日主力资金净流出838.66万元，游资资金净流入1063.44万元，散户资金净流出224.78万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600000877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002252","BK0028","BK0188","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785959095922,"stockEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":0.0929},{"period":"3month","weight":-0.0833},{"period":"6month","weight":-0.1904},{"period":"1year","weight":-0.266},{"period":"ytd","weight":-0.1943}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":-0.0403},{"period":"3month","weight":-0.0722},{"period":"6month","weight":-0.046},{"period":"1year","weight":0.0721},{"period":"ytd","weight":-0.0228}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"121087人(较上一季度增加2.01%)","perCapita":"54409股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"659267万元","survey":" 上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}